Drug intelligence / Profile preview

Clorindione

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

Clorindione is a synthetic anticoagulant of the indandione class. It acts as a vitamin K antagonist, inhibiting the synthesis of vitamin K-dependent clotting factors in the liver. This mechanism is similar to that of other oral anticoagulants like warfarin and phenindione. Clorindione has been used primarily for the prevention and treatment of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism. Its use has largely been replaced by safer or more effective alternatives due to concerns about side effects, including bleeding risk.

Other names: 2-chloro-1,3-indandione

Targets

VKORC1 (Vitamin K epoxide reductase complex subunit 1)

Beyond the preview

Go deeper on Clorindione.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clorindione.

Explore the full profile